Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives

Drug Target Insights - New Zealand
doi 10.1177/117739280700200012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Erectile Dysfunction: Current Concepts and Future Directions

Archives of Andrology
2003English

Quantitative Risk-Benefit Analysis of Oral Phosphodiesterase Type 5 Inhibitors on Erectile Dysfunction Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction in Spinal Cord-Injured Men

Spinal Cord
MedicineNeurologyRehabilitation
2006English

Erectile Dysfunction: Current Investigation and Management

Journal of Family Planning and Reproductive Health Care
2005English

Current Diagnosis and Management of Erectile Dysfunction

Current Sexual Health Reports
2014English

Testosterone Level and Endothelial Dysfunction in Patients With Vasculogenic Erectile Dysfunction

Andrology
EndocrinologyReproductive MedicineUrologyMetabolismDiabetes
2017English

The Pathophysiology of Erectile Dysfunction Related to Endothelial Dysfunction and Mediators of Vascular Function

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2002English

Effects of Metformin on Endothelial Health and Erectile Dysfunction

Translational Andrology and Urology
Reproductive MedicineUrology
2017English

Diabetes and Sexual Dysfunction: Current Perspectives

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy